This one's getting a lot of attention: TechCrunch reports that Freenome, a two-year-old liquid biopsy company, has raised $65 million in Series A funds from investors led by Andreessen Horowitz. There are a lot of companies in this space now, trying to detect cancer from a patient's DNA, but they haven't been able to tell exactly where a cancer is growing or whether it can be treated. The difference, Freenome cofounder and CEO Gabe Otte told TechCrunch, is that "we capture all the [genetic material floating in our blood] rather than fixating on a few mutations known to be associated with cancer."
New: A daily newsletter defining what matters in business and markets
More stories loading.